Öz
Kaynakça
- 1. Teleanu, R.I., et al., Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. 2019. 9(1): p. 84.
- 2. Folkman, J.J.N.e.j.o.m., Tumor angiogenesis: therapeutic implications. 1971. 285(21): p. 1182-1186.
- 3. Ayoub, N.M., et al., Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. 2022. 13.
- 4. Lugano, R., et al., Tumor angiogenesis: causes, consequences, challenges and opportunities. 2020. 77(9): p. 1745-1770.
- 5. Liu, G., et al., Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer. 2015. 36(3): p. 2185-2191.
- 6. Zhao, Y. and A.A.J.T.o. Adjei, Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. 2015. 20(6): p. 660-673.
- 7. Hu, H., et al., The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. 2022. 13: p. 802846.
- 8. Das, M. and H.J.E.o.o.t.t. Wakelee, Targeting VEGF in lung cancer. 2012. 16(4): p. 395-406.
- 9. Goel, H.L. and A.M.J.N.R.C. Mercurio, VEGF targets the tumour cell. 2013. 13(12): p. 871-882.
- 10. Qin, S.-Y., et al., Drug self-delivery systems for cancer therapy. 2017. 112: p. 234-247.
- 11. Asada, H., et al., Preparation and structures of trinuclear manganese (II) complexes with N-2-pyridiylmethylidene-2-hydroxy-5-substituted-phenylamine. 2003. 6(2): p. 193-196.
- 12. Saeed, A.M., S.S. AlNeyadi, and I.M. Abdou, Anticancer activity of novel Schiff bases and azo dyes derived from 3-amino-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione. 2020. 26(1): p. 192-205.
- 13. Miri, R., N. Razzaghi-asl, and M.K.J.J.o.m.m. Mohammadi, QM study and conformational analysis of an isatin Schiff base as a potential cytotoxic agent. 2013. 19(2): p. 727-735.
- 14. Pandey, A., et al., Synthesis of Schiff bases of 2-amino-5-aryl-1, 3, 4-thiadiazole and its analgesic, anti-inflammatory and anti-bacterial activity. 2012. 9(4): p. 2524-2531.
- 15. Ünver, Y., et al., Synthesis of new 1, 2, 4-triazole compounds containing Schiff and Mannich bases (morpholine) with antioxidant and antimicrobial activities. 2016. 31(sup3): p. 89-95.
- 16. GÜMRÜKÇÜOĞLU, N. and B.B.J.G.U.J.o.S. SÖKMEN, Synthesis of New Ligands Containing Azomethine Group and Investigation of Antioxidant, Antiurease Activities. 33(3): p. 662-671.
- 17. Sathe, B.S., et al., Synthesis characterization and anti-inflammatory evaluation of new fluorobenzothiazole schiff’s bases. 2011. 3(3): p. 164-169.
- 18. Stefanou, D., et al., Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. 2004.
- 19. Carrillo de Santa Pau, E., et al., Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. 2009. 115(8): p. 1701-1712.
- 20. Riely, G.J. and V.A.J.C.c.r. Miller, Vascular endothelial growth factor trap in non–small cell lung cancer. 2007. 13(15): p. 4623s-4627s.
- 21. Montanino, A., et al., Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol, 2021. 11: p. 655316.
- 22. Pàez-Ribes, M., et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. 2009. 15(3): p. 220-231.
- 23. Aslan, H.G., S. Akkoç, and Z.J.I.C.C. Kökbudak, Anticancer activities of various new metal complexes prepared from a Schiff base on A549 cell line. 2020. 111: p. 107645.
Öz
Objective: Lung cancer is one of the most common cancers in the world. It is known that angiogenesis plays a role in the development and metastasis of lung cancer. Azomethine derivatives known as Schiff bases have many biological activities. In this study, we aimed to determine the anticancer activity of the newly synthesized azomethine derivative compound B-47/2 on lung cancer and to determine the effect of this component on vascular endothelial growth factor B (VEGFB) gene expression.
Material and Method: Compound B-47/2 was synthesized for the first time. B-47/2 compound was applied to lung cancer cell line (A549) at varying concentrations (1-100 µg/mL) and its anticancer activity was found after 24, 48 and 72 hours incubations using the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) method. The half maximal inhibitory concentration (IC50) dose of B-47/2 was applied to the cells and ribonucleic acid (RNA) isolation followed by complementary deoxyribonucleic acid (cDNA) synthesis was performed. Then, reverse transcription-polymerase chain reaction (RT-PCR) method was used to determine the expression level of VEGFB gene.
Results: As a result, it was determined that the B-47/2 compound applied to the A-549 cell line showed the highest cytotoxic activity after 72 hours of incubation. In addition, it was determined that the B-47/2 compound decreased the expression of the VEGFB gene.
Discussion: There are studies in which the anticancer activity of azomethine derivatives has been observed. The topic of synthesizing new drugs to prevent cancer is popular. We suggested that the newly synthesized component may have anticancer activity and may be effective on angiogenesis.
Anahtar Kelimeler
Angiogenesis lung cancer cytotoxicity gene expression azomethine derivatives
Kaynakça
- 1. Teleanu, R.I., et al., Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. 2019. 9(1): p. 84.
- 2. Folkman, J.J.N.e.j.o.m., Tumor angiogenesis: therapeutic implications. 1971. 285(21): p. 1182-1186.
- 3. Ayoub, N.M., et al., Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. 2022. 13.
- 4. Lugano, R., et al., Tumor angiogenesis: causes, consequences, challenges and opportunities. 2020. 77(9): p. 1745-1770.
- 5. Liu, G., et al., Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer. 2015. 36(3): p. 2185-2191.
- 6. Zhao, Y. and A.A.J.T.o. Adjei, Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. 2015. 20(6): p. 660-673.
- 7. Hu, H., et al., The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. 2022. 13: p. 802846.
- 8. Das, M. and H.J.E.o.o.t.t. Wakelee, Targeting VEGF in lung cancer. 2012. 16(4): p. 395-406.
- 9. Goel, H.L. and A.M.J.N.R.C. Mercurio, VEGF targets the tumour cell. 2013. 13(12): p. 871-882.
- 10. Qin, S.-Y., et al., Drug self-delivery systems for cancer therapy. 2017. 112: p. 234-247.
- 11. Asada, H., et al., Preparation and structures of trinuclear manganese (II) complexes with N-2-pyridiylmethylidene-2-hydroxy-5-substituted-phenylamine. 2003. 6(2): p. 193-196.
- 12. Saeed, A.M., S.S. AlNeyadi, and I.M. Abdou, Anticancer activity of novel Schiff bases and azo dyes derived from 3-amino-4-hydroxy-2H-pyrano[3,2-c]quinoline-2,5(6H)-dione. 2020. 26(1): p. 192-205.
- 13. Miri, R., N. Razzaghi-asl, and M.K.J.J.o.m.m. Mohammadi, QM study and conformational analysis of an isatin Schiff base as a potential cytotoxic agent. 2013. 19(2): p. 727-735.
- 14. Pandey, A., et al., Synthesis of Schiff bases of 2-amino-5-aryl-1, 3, 4-thiadiazole and its analgesic, anti-inflammatory and anti-bacterial activity. 2012. 9(4): p. 2524-2531.
- 15. Ünver, Y., et al., Synthesis of new 1, 2, 4-triazole compounds containing Schiff and Mannich bases (morpholine) with antioxidant and antimicrobial activities. 2016. 31(sup3): p. 89-95.
- 16. GÜMRÜKÇÜOĞLU, N. and B.B.J.G.U.J.o.S. SÖKMEN, Synthesis of New Ligands Containing Azomethine Group and Investigation of Antioxidant, Antiurease Activities. 33(3): p. 662-671.
- 17. Sathe, B.S., et al., Synthesis characterization and anti-inflammatory evaluation of new fluorobenzothiazole schiff’s bases. 2011. 3(3): p. 164-169.
- 18. Stefanou, D., et al., Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. 2004.
- 19. Carrillo de Santa Pau, E., et al., Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. 2009. 115(8): p. 1701-1712.
- 20. Riely, G.J. and V.A.J.C.c.r. Miller, Vascular endothelial growth factor trap in non–small cell lung cancer. 2007. 13(15): p. 4623s-4627s.
- 21. Montanino, A., et al., Angiogenesis Inhibitors in Small Cell Lung Cancer. Front Oncol, 2021. 11: p. 655316.
- 22. Pàez-Ribes, M., et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. 2009. 15(3): p. 220-231.
- 23. Aslan, H.G., S. Akkoç, and Z.J.I.C.C. Kökbudak, Anticancer activities of various new metal complexes prepared from a Schiff base on A549 cell line. 2020. 111: p. 107645.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Konular | Sağlık Kurumları Yönetimi |
| Bölüm | Temel Tıp Bilimleri Araştırma Yazıları |
| Yazarlar | |
| Yayımlanma Tarihi | 31 Aralık 2022 |
| Kabul Tarihi | 19 Aralık 2022 |
| Yayımlandığı Sayı | Yıl 2022Cilt: 44 Sayı: 4 |